Moderate (40 to 70%)

Spectrum of Activity


General Information

  • Pneumonia
  • UTIs
  • URIs

Renal Function

Diarrhea1 7%
Increased LFTs 4%
Nausea 3.3%
Eosinophilia 3%
Vulvovaginal Infections 1.3%
Vaginal Fungal Infections 1%
Abdominal Pain 1.2%
Headache 1.0%
Neutropenia, thrombocytopenia Rare

1 - Diarrhea - dose-related:

  • 10.4% of patients receiving 800 mg per day
  • 5.7% for those receiving 200 mg per day
  • Of patients with diarrhea, 10% had C. difficile organism or toxin in the stool.


Concomitant administration of H2-antagonists reduces Cmax by approximately 33% and AUC by 28%. The clinical significance of these data is unclear.

  • PK/PD: Time above MIC
  • Protein Binding: 40%
  • Average serum Half-life: 2.5 hrs.

Cefpodoxime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Cefpodoxime has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria.

Resistance Mechanisms: Resistance to Cefpodoxime is primarily through hydrolysis by beta-lactamase, alteration of penicillin-binding proteins (PBPs), and decreased permeability.

  • 3rd generation cephalosporin
  • Cefpodoxime is known to occasionally induce a positive direct Coombs' test.
  • Cefpodoxime carries the same R1 side chain as cefotaxime, ceftriaxone, and cefepime. Cross-allergenicity may occur.